



**Dr. Bradley C. Carthon**

Dr. Carthon graduated from Hampton University in 1996 with honors as a Biology Major and Chemistry Minor. He went on to receive his M.D. and Ph.D. degrees from Harvard Medical School and Harvard University in 2005, where he studied the roles of cell cycle proteins in mammary gland and breast cancer development. He remained in Boston for his residency in Internal Medicine at the Massachusetts General Hospital.

Dr. Carthon then did his Medical Oncology Fellowship training at the University of Texas M.D. Anderson Cancer Hospital. While at M.D. Anderson, he chose to focus on Genitourinary Medical Oncology and worked on Caveolin-1 as a biomarker of prostate cancer bone metastases.

Dr. Carthon joined Winship Cancer Institute of Emory University in Atlanta in 2011. He serves as a member of the Genitourinary Oncology Group and Phase I Early Discovery Unit. His interest is in novel therapeutic targets and clinical trials that utilize treatment combinations for patients with prostate, bladder, testicular, and kidney cancers, as well as a broad array of solid tumors within the Winship Phase I group. He is principal investigator on numerous genitourinary and phase I clinical trials. He is currently Associate Professor of GU Medical Oncology and serves as Chief of Hematology Oncology at Emory Winship Midtown. He is currently serving as Interim Director, Division of Medical Oncology.

Dr. Carthon has served as an ASCO University Faculty member and as a member of the ASCO PSA Screening Task Force. He is currently Track Leader and member of the ASCO Annual Meeting Education Committee for Prostate Cancer and is a member of the NRG Cooperative Group Early Phase Clinical Trials Safety Committee. He has an interest in health disparities, and has served as Chair of the Winship Cancer Institute Health Disparities, Health Literacy and Minority Accrual Committee.